Refine
Year of publication
Document Type
- Preprint (688)
- Article (508)
- Conference Proceeding (3)
- Working Paper (1)
Has Fulltext
- yes (1200)
Is part of the Bibliography
- no (1200)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- HIV (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- breast cancer (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- coronavirus (3)
- pp collisions (3)
- Beauty production (2)
- Breast cancer (2)
- COVID-19 (2)
- CRM (2)
- Charm physics (2)
- Diagnostik (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Heavy Quark Production (2)
- Hepatitis C virus (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Single electrons (2)
- biomarker (2)
- brain metastases (2)
- cirrhosis (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- guidelines (2)
- reference values (2)
- screening (2)
- stroke (2)
- 900 GeV (1)
- AA-amylodosis (1)
- ABC transporters (1)
- ACLF (1)
- ADHD (1)
- ALICE detector (1)
- APRI (1)
- ASAP (1)
- ATAD2 (1)
- ATPases (1)
- Abrasion (1)
- Adverse events (1)
- Alien (1)
- Alternating Phase Focusing (1)
- Anti-nuclei (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Artesunate (1)
- Atmospheric science (1)
- B cell subpopulations (1)
- BRCA1 (1)
- BRCA2 (1)
- BRD2 (1)
- BRD4 (1)
- BROMO-10 (1)
- Baryonic resonances (1)
- Beam dynamics simulation (1)
- Big Five (1)
- Biodiversity (1)
- Biogeographical representativeness (1)
- Boosted Jets (1)
- CD16 (1)
- CD56 (1)
- CDH13 (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Central nervous system metastases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Chemoradiotherapy (1)
- Chemorefractory advanced gastric cancer (1)
- Child (1)
- Child abuse (1)
- Children (1)
- Chronic kidney disease (1)
- Cirrhosis (1)
- Claims on land (1)
- Climate change (1)
- Clinical genetics (1)
- Clinical study (1)
- Clinical variation (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Consensus (1)
- Continuous wave (1)
- Cytoskeleton (1)
- Data management (1)
- Decision trees (1)
- Decontamination (1)
- Dental air (1)
- Dental implants (1)
- Depression (1)
- Dermatomyositis (1)
- Devic disease (1)
- Devic syndrome (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Docetaxel (1)
- Drug therapy (1)
- EBV (1)
- Ecosystem integrity (1)
- Ecosystem services (1)
- Ecosystems (1)
- Elderly (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Emotions (1)
- Entomology (1)
- Environment (1)
- Ephrin-B2–EphB4 (1)
- Essential biodiversity variables (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exosomes (1)
- Experimental models of disease (1)
- FIB-4 (1)
- FOLFIRI (1)
- FXIII deficiency (1)
- Factor XIII (1)
- Falciparum (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First site of metastatic disease (1)
- First-line combination antiretroviral therapy (1)
- Forensic examination (1)
- Forschung (1)
- Frailty (1)
- Freezeout (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics research (1)
- Genomic instability (1)
- German PID-NET registry (1)
- Gleason Score (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HIV-1 (1)
- HIV-RNA (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Heavy-ion reactions (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Human behaviour (1)
- Human well-being (1)
- Hyperons (1)
- Hypertension (1)
- IHC (1)
- IVDU (1)
- IgG substitution therapy (1)
- Immunology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- LTER (1)
- Lehre (1)
- Linear accelerator (1)
- Liver diseases (1)
- Liver enzymes (1)
- Liver transplantation (1)
- Long-term ecological monitoring (1)
- Long‐term ecosystem research (1)
- MRI (1)
- MS (1)
- Malaria (1)
- Material budget (1)
- Mental health and psychiatry (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular medicine (1)
- Molecular neuroscience (1)
- Mongolian spot (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Myanmar (1)
- NK cells (1)
- NMO-IgG (1)
- NSAIDs (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neuromyelitis optica (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Noninferiority (1)
- Nonlinear beam dynamics (1)
- Nuclear modification factor (1)
- Nucleus (1)
- ORL (1)
- Observation (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- Osteoporosis (1)
- Otorhinolaryngology (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Peri-implantitis (1)
- Personalized medicine (1)
- Phylogenomics (1)
- Physiology (1)
- Plasmodium (1)
- Population genetics (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Predictive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Psychometrics (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Questionnaires (1)
- Quinine (1)
- Rapidity Range (1)
- Regression analysis (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SF-36 (1)
- Severe malaria (1)
- Single muons (1)
- Site networks (1)
- Socio-ecology (1)
- Specialist training (1)
- Stentoplasty (1)
- Storage ring (1)
- Strangeness (1)
- Sunitinib (1)
- Sustainability (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- TR (1)
- Teaching (1)
- Thrombosis (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Tyrosine kinase inhibitor (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGF (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- WHO-5 (1)
- Weiterbildung (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- acute-on-chronic liver failure (1)
- acute‐on‐chronic liver failure (1)
- advanced breast cancer (1)
- agreeableness (1)
- allogeneic transplantation (1)
- androgen receptor (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-retroviral agents (1)
- antibiotic resistance (1)
- antibiotics (1)
- antihormone therapy (1)
- aquaporin-4 (AQP4) antibody (1)
- asymptomatic (1)
- autoimmunity (1)
- binary nucleation (1)
- bioprinting (1)
- biosecurity (1)
- blood hiv rna (1)
- body-on-a-chip (1)
- bortezomib (1)
- bromodomain inhibitor (1)
- cART (1)
- cancer therapy (1)
- castration-resistant prostate cancer (1)
- cd4 count determination procedure (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- children (1)
- chromatin (1)
- circulation (1)
- clinical features (1)
- co-infection (1)
- complement system (1)
- concept (1)
- concordance (1)
- conservation (1)
- cryo-EM (1)
- dE/dx (1)
- detector (1)
- downgrading (1)
- e-Health (1)
- emergency care (1)
- epidemiology (1)
- everolimus (1)
- excipients (1)
- executive functions (1)
- exercise (1)
- exotic (1)
- experimental results (1)
- expertise (1)
- exponential model (1)
- fecal microbiota transfer (1)
- fibrotest (1)
- flow cytometry (1)
- fusion biopsy (1)
- graft-vs-host disease (1)
- health (1)
- heart-on-a-chip (1)
- heavy ion experiments (1)
- hemodynamic (1)
- hepatitis C (1)
- hiv (1)
- hospital admission (1)
- human allogeneic hematopoietic cell transplantation (1)
- human immunodeficiency virus (1)
- human intestinal microbiota (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- impact (1)
- induction regimen (1)
- inflammation (1)
- invasion (1)
- ion‐induced nucleation (1)
- kidney (1)
- kidney-on-a-chip (1)
- lantibiotic (1)
- lapatinib (1)
- lenalidomide (1)
- lipoprotein (1)
- liver-on-a-chip (1)
- lockdowns (1)
- longitudinally extensive transverse myelitis (1)
- lung-on-a-chip (1)
- magnetic resonance imaging (1)
- male (1)
- management (1)
- mass spectrometry (1)
- mechanical ventilation (1)
- membrane proteins (1)
- metastatic (1)
- metastatic renal cell carcinoma (1)
- micro-physiological systems (1)
- molecular machines (1)
- mortality (1)
- multiple myeloma (1)
- native (1)
- neurodevelopment (1)
- nisin binding (1)
- non-invasive fibrosis assessment (1)
- nonnative (1)
- nuclear magnetic resonance (NMR) (1)
- organs-on-a-chip (1)
- pain (1)
- pertuzumab (1)
- phase IV (1)
- phylogeny (1)
- physical activity (1)
- pleiotropy (1)
- pneumocystis carinii (1)
- pneumocystis pneumonia (1)
- pneumonia (1)
- point shear wave elastography (1)
- prevention (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- prognostic scores (1)
- prophylaxis (1)
- prostate cancer (1)
- prostate neoplasm (1)
- protein structure (1)
- psychological health (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radical prostatectomy (1)
- recurrent optic neuritis (1)
- registry for primary immunodeficiency (1)
- renal failure (1)
- respiratory failure (1)
- risk (1)
- second-line (1)
- seed and soil (1)
- sequence alignment (1)
- simulation (1)
- simulation training (1)
- skin-on-a-chip (1)
- small angle x-ray scattering (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- stakeholder (1)
- structural biology (1)
- systematic biopsy (1)
- telemedicine (1)
- thrombolysis (1)
- thrombolysis (tPA) (1)
- training (1)
- transient elastography (1)
- trastuzumab (1)
- uncertainty (1)
- upgrading (1)
- valuation (1)
- working memory (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1088)
- Frankfurt Institute for Advanced Studies (FIAS) (957)
- Informatik (920)
- Medizin (72)
- Geowissenschaften (12)
- Biochemie und Chemie (7)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- ELEMENTS (3)
- Informatik und Mathematik (3)
Genetic generalised epilepsy (GGE) is the most common form of genetic epilepsy, accounting for 20% of all epilepsies. Genomic copy number variations (CNVs) constitute important genetic risk factors of common GGE syndromes. In our present genome-wide burden analysis, large (≥ 400 kb) and rare (< 1%) autosomal microdeletions with high calling confidence (≥ 200 markers) were assessed by the Affymetrix SNP 6.0 array in European case-control cohorts of 1,366 GGE patients and 5,234 ancestry-matched controls. We aimed to: 1) assess the microdeletion burden in common GGE syndromes, 2) estimate the relative contribution of recurrent microdeletions at genomic rearrangement hotspots and non-recurrent microdeletions, and 3) identify potential candidate genes for GGE. We found a significant excess of microdeletions in 7.3% of GGE patients compared to 4.0% in controls (P = 1.8 x 10-7; OR = 1.9). Recurrent microdeletions at seven known genomic hotspots accounted for 36.9% of all microdeletions identified in the GGE cohort and showed a 7.5-fold increased burden (P = 2.6 x 10-17) relative to controls. Microdeletions affecting either a gene previously implicated in neurodevelopmental disorders (P = 8.0 x 10-18, OR = 4.6) or an evolutionarily conserved brain-expressed gene related to autism spectrum disorder (P = 1.3 x 10-12, OR = 4.1) were significantly enriched in the GGE patients. Microdeletions found only in GGE patients harboured a high proportion of genes previously associated with epilepsy and neuropsychiatric disorders (NRXN1, RBFOX1, PCDH7, KCNA2, EPM2A, RORB, PLCB1). Our results demonstrate that the significantly increased burden of large and rare microdeletions in GGE patients is largely confined to recurrent hotspot microdeletions and microdeletions affecting neurodevelopmental genes, suggesting a strong impact of fundamental neurodevelopmental processes in the pathogenesis of common GGE syndromes.
Background: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.
Methods: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria.
Results: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.
Conclusion: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.
Introduction: Metabolic acidosis during hemorrhagic shock is common and conventionally considered to be due to hyperlactatemia. There is increasing awareness, however, that other nonlactate, unmeasured anions contribute to this type of acidosis.
Methods: Eleven anesthetized dogs were hemorrhaged to a mean arterial pressure of 45 mm Hg and were kept at this level until a metabolic oxygen debt of 120 mLO2/kg body weight had evolved. Blood pH, partial pressure of carbon dioxide, and concentrations of sodium, potassium, magnesium, calcium, chloride, lactate, albumin, and phosphate were measured at baseline, in shock, and during 3 hours post-therapy. Strong ion difference and the amount of weak plasma acid were calculated. To detect the presence of unmeasured anions, anion gap and strong ion gap were determined. Capillary electrophoresis was used to identify potential contributors to unmeasured anions.
Results: During induction of shock, pH decreased significantly from 7.41 to 7.19. The transient increase in lactate concentration from 1.5 to 5.5 mEq/L during shock was not sufficient to explain the transient increases in anion gap (+11.0 mEq/L) and strong ion gap (+7.1 mEq/L), suggesting that substantial amounts of unmeasured anions must have been generated. Capillary electrophoresis revealed increases in serum concentration of acetate (2.2 mEq/L), citrate (2.2 mEq/L), alpha-ketoglutarate (35.3 microEq/L), fumarate (6.2 microEq/L), sulfate (0.1 mEq/L), and urate (55.9 microEq/L) after shock induction.
Conclusion: Large amounts of unmeasured anions were generated after hemorrhage in this highly standardized model of hemorrhagic shock. Capillary electrophoresis suggested that the hitherto unmeasured anions citrate and acetate, but not sulfate, contributed significantly to the changes in strong ion gap associated with induction of shock.
Background: There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with the prevalence of pathogenic gBRCA mutations in this patient group.
Methods: The study comprised 802 women (median age 40 years, range 19–76) with oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic gBRCA mutation.
Results: A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.1%). The mutation prevalence was 32.9% in the age group 20–29 years compared to 6.9% in the age group 60–69 years. Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds ratio 1.87 per 10 year decrease, 95%CI 1.50–2.32, p < 0.001). gBRCA mutation risk was predicted to be > 10% for women diagnosed below approximately 50 years.
Conclusions: Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic gBRCA mutation.
Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection.
Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger relation to PFS (HR 0.36, p = 0.008) than baseline patient parameters, including IMDC score. Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS (HR 0.21, p < 0.001). mTOR polymorphisms appeared to be associated with therapy response but were not significant. Hence, we identified TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.
Gemas Artikel 11 der FFH-Richtlinie ist ein Monitoring des Erhaltungszustandes der Arten von gemeinschaftlicher Bedeutung durchzufuhren. Weiterhin ist nach Artikel 12 eine fortlaufende Überwachung des unbeabsichtigten Fangs oder Tötens der Anhang IV-Tierarten vorgeschrieben, worauf gegebenenfalls weiterführende Erhaltungsmaßnahmen und Forschung aufbauen sollen. Im § 40 BNatSchG wird dieses Monitoring in die Verantwortung der Bundesländer übergeben.
Guanine quadruplex (G-quadruplex) motifs in the 5′ untranslated region (5′-UTR) of mRNAs were recently shown to influence the efficiency of translation. In the present study, we investigate the interaction between cellular proteins and the G-quadruplexes located in two mRNAs (MMP16 and ARPC2). Formation of the G-quadruplexes was confirmed by biophysical characterization and the inhibitory activity on translation was shown by luciferase reporter assays. In experiments with whole cell extracts from different eukaryotic cell lines, G-quadruplex-binding proteins were isolated by pull-down assays and subsequently identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The binding partners of the RNA G-quadruplexes we discovered included several heterogenous nuclear ribonucleoproteins, ribosomal proteins, and splicing factors, as well as other proteins that have previously not been described to interact with nucleic acids. While most of the proteins were specific for either of the investigated G-quadruplexes, some of them bound to both motifs. Selected candidate proteins were subsequently produced by recombinant expression and dissociation constants for the interaction between the proteins and RNA G-quadruplexes in the low nanomolar range were determined by surface plasmon resonance spectroscopy. The present study may thus help to increase our understanding of the mechanisms by which G-quadruplexes regulate translation.
Understanding the diverging opinions of academic experts, stakeholders and the public is important for effective conservation management. This is especially so when a consensus is needed for action to minimize future risks but the knowledge upon which to base this action is uncertain or missing. How to manage non-native, invasive species (NIS) is an interesting case in point: the issue has long been controversial among stakeholders, but publicly visible, major disagreement among experts is recent. To characterize the multitude of experts’ understanding and valuation of non-native, NIS we performed structured qualitative interviews with 26 academic experts, 13 of whom were invasion biologists and 13 landscape experts. Within both groups, thinking varied widely, not only about basic concepts (e.g., non-native, invasive) but also about their valuation of effects of NIS. The divergent opinions among experts, regarding both the overall severity of the problem in Europe and its importance for ecosystem services, contrasted strongly with the apparent consensus that emerges from scientific synthesis articles and policy documents. We postulate that the observed heterogeneity of expert judgments is related to three major factors: (1) diverging conceptual understandings, (2) lack of empirical information and high scientific uncertainties due to complexities and contingencies of invasion processes, and (3) missing deliberation of values. Based on theory from science studies, we interpret the notion of an NIS as a boundary object, i.e., concepts that have a similar but not identical meaning to different groups of experts and stakeholders. This interpretative flexibility of a concept can facilitate interaction across diverse groups but bears the risk of introducing misunderstandings. An alternative to seeking consensus on exact definitions and risk assessments would be for invasive species experts to acknowledge uncertainties and engage transparently with stakeholders and the public in deliberations about conflicting opinions, taking the role of honest brokers of policy alternatives rather than of issue advocates.
Tumor–endothelial cell interactions represent an essential mechanism in spinal metastasis. Ephrin-B2–EphB4 communication induces tumor cell repulsion from the endothelium in metastatic melanoma, reducing spinal bone metastasis formation. To shed further light on the Ephrin-B2–EphB4 signaling mechanism, we researched the effects of pharmacological EphB4 receptor stimulation and inhibition in a ligand-dependent/independent context. We chose a preventative and a post-diagnostic therapeutic window. EphB4 stimulation during tumor cell seeding led to an increase in spinal metastatic loci and number of disseminated melanoma cells, as well as earlier locomotion deficits in the presence of endothelial Ephrin-B2. In the absence of endothelial Ephrin-B2, reduction of metastatic loci with a later manifestation of locomotion deficits occurred. Thus, EphB4 receptor stimulation affects metastatic dissemination depending on the presence/absence of endothelial Ephrin-B2. After the manifestation of solid metastasis, EphB4 kinase inhibition resulted in significantly earlier manifestation of locomotion deficits in the presence of the ligand. No post-diagnostic treatment effect was found in the absence of endothelial Ephrin-B2. For solid metastasis treatment, EphB4 kinase inhibition induced prometastatic effects in the presence of endothelial Ephrin-B2. In the absence of endothelial Ephrin-B2, both therapies showed no effect on the growth of solid metastasis.
Simple Summary: The incidence of brain metastases from breast cancer is increasing and the treatment is still a major challenge. Several scores have been developed in order to estimate the prognosis of patients with brain metastases by objective criteria. Here, we validated all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer patients with brain metastases in the Brain Metastases in the German Breast Cancer (BMBC) registry. Although all three available GPA-scores were associated with OS, they all show limitations mainly in predicting short-term (below 3 months) survival but also in long-term (above 12 months) survival. We discuss the test performances of all scores in our work and provide evidence how physicians should use them as a tool to select patients for different treatment options.
Abstract: Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis (p < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.